AURELIUS Group sells ISOCHEM Hungarian subsidiary Framochem

01.08.2014

AURELIUS Group sells ISOCHEM Hungarian subsidiary Framochem

  • Sale to strategic investor from the United States following acquisition in 2010 and successful restructuring
  • Capital employed multiplied
  • Already third successful exit in 2014, transaction pipeline remains well filled

Munich, August 1, 2014 – ISOCHEM S.A.S, a company of the Munich-based AURELIUS Group (ISIN DE000A0JK2A8), has sold its Hungary-based subsidiary Framochem Kft together with its Germany-based sales unit ISOCHEM Deutschland GmbH to VanDeMark Chemical Inc. headquartered in Lockport, NY, USA. Acquired from the French state-owned enterprise SNPE in 2010, ISOCHEM is a leading supplier of fine chemicals to customers in the pharmaceuticals industry, cosmetics, and the specialty and agrochemical industries. Framochem, which does not form part of ISOCHEM’s core business, generated revenues of EUR 27.1 million and an operating profit (EBITDA) of around EUR 5.9 million in 2013. 

Framochem is one of the biggest independent producers of phosgene-based fine chemicals in the world. Its products are used in a wide range of highly attractive fields, including medication, agrochemicals, entertainment electronics and lithium-ion batteries for the automotive industry. Over recent years, the Hungarian subsidiary has been successfully set up as an independent activity and realigned. Besides spending on research and development, the focus was on producing and distributing value-added products and expanding the customer base. All in all, this helped to secure major improvements to operations and an increase in revenues of over 20 percent since the acquisition. The sales proceeds will have a very positive impact on results in the third quarter of 2014. 

The buyer is VanDeMark Chemical Inc., a portfolio company of the US-based private equity investor Uni-World Capital, L.P. The acquisition will give it access to a much broader customer base and enable it to significantly increase its revenues. Together, the companies will become a leading global player in this field. “The disposal represents another great transaction. Everyone involved will benefit greatly from the move,” comments Donatus Albrecht, the member of the AURELIUS Executive Board responsible for M&A activities. “Our pipeline is very well filled on both the acquisition and exit side for the second half of the year as well. 2014 is set to be yet another record year for AURELIUS.”

A telephone conference is being held in English for interested investors and journalists at 2pm on Tuesday, August 5, 2014. The Management Board of AURELIUS AG will report on the sale of Framochem and the present busy period of transaction activity.

Please send us an email to  to register.